Biomarker-Driven Treatment Selection in mCSPC

Panelists discuss how biomarker and molecular profiling are becoming increasingly relevant in metastatic castration-sensitive prostate cancer (mCSPC), providing a foundation for precision medicine even before progression to castration-resistant disease. Genetic testing for DNA-repair mutations such as BRCA1/2 or ATM identifies patients who may later benefit from PARP inhibitors or clinical trials. Early molecular insight also aids family counseling and informs long-term surveillance planning.

Panelists discuss how practical barriers—sample access, reimbursement, and turnaround times—are being addressed through streamlined workflows and patient education. Clinicians emphasize that results guide, not dictate, therapy and reassure patients that effective androgen receptor pathway inhibitor–based treatments remain standard for most. Importantly, ensuring equitable testing across community and academic sites prevents disparities in future treatment access.

Panelists discuss how the integration of molecular data enhances confidence in therapeutic sequencing and empowers shared decision-making. Knowing a patient’s genetic landscape today helps anticipate tomorrow’s options, ensuring continuity of personalized care.